To resolve whether CaMKK2 in stromal cells or the tumor itself might drive tumor progression, we sought to determine if CaMKK2 deficiency in the tumor-bearing host was sufficient to extend survival in syngeneic orthotopically implanted glioma models. The gene discussed is CAMKK2; the disease is neoplasm.